Stocks · News reference
GlucoTrack shares are trading higher after the company announced its subsidiary, Lōkahi Therapeutics, engaged two ai PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glucotrack's Lōkahi Therapeutics Announces Partnership With Pepperdine Business School For MBA Students To Evaluate Drug Assets
8-K filing — Glucotrack, Inc. (GCTK)
Filed: 2026-09-24 AccNo: 0001493152-26-044182 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
What's Going On With GlucoTrack Shares On Thursday?
GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.